Research Analysts Set Expectations for GLSI FY2024 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings estimates for Greenwich LifeSciences in a report released on Tuesday, February 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.80) per share for the year, up from their previous forecast of ($0.81). HC Wainwright currently has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Greenwich LifeSciences' FY2025 earnings at ($0.81) EPS.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ GLSI traded up $0.13 during midday trading on Friday, hitting $12.51. 23,038 shares of the company traded hands, compared to its average volume of 35,066. Greenwich LifeSciences has a 12-month low of $10.52 and a 12-month high of $21.44. The stock has a 50-day moving average price of $12.56 and a 200 day moving average price of $13.43. The firm has a market cap of $164.45 million, a P/E ratio of -15.63 and a beta of 1.69.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of the business's stock in a transaction on Friday, January 10th. The shares were acquired at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the acquisition, the chief executive officer now owns 5,552,502 shares in the company, valued at $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have acquired 10,500 shares of company stock worth $128,459. 51.67% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences in the third quarter worth about $253,000. State Street Corp lifted its stake in shares of Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after buying an additional 3,005 shares in the last quarter. Barclays PLC lifted its stake in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after buying an additional 6,538 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after buying an additional 4,465 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.